DNA vaccination and gene therapy: optimization and delivery for cancer therapy

被引：39

作者：

Bodles-Brakhop, Angela M. ^{[1
]}

Draghia-Akli, Ruxandra ^{[1
]}

机构：

[1] VGX Pharmaceut Inc, The Woodlands, TX 77381 USA

来源：

EXPERT REVIEW OF VACCINES | 2008年 / 7卷 / 07期

关键词：

cancer; DNA vaccine; electroporation; immune therapy; plasmid;

D O I：

10.1586/14760584.7.7.1085

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This review will focus on DNA vaccine approaches for the prevention or treatment of cancer and its complications. DNA vaccine therapies are a relatively novel method of cancer treatment with the goal to induce immunity against tumor-associated antigens. Both viral and nonviral vaccines have been tested in preclinical and clinical models with variable success. However, the development of new delivery methods, such as electroporation, as well as the use of agents that improve antigen uptake or presentation, and the optimization of the transgene sequences, are overcoming historical drawbacks, Efficacy and safety issues of the in vivo use of DNA-based vaccines, as well as data from preclinical and recent clinical studies, are discussed. Novel developments will improve clinical efficacy, with the potential for DNA vaccination to enter in to the arsenal of cancer therapies in the near future.

引用

页码：1085 / 1101

页数：17

共 113 条

[1] Current immunotherapeutic strategies in malignant melanoma [J].

Agostino, Nicole M. ;

Ali, Arjumand ;

Nair, Suresh G. ;

Mosca, Paul J. .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (04) :945-+

[2] A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization [J].

Ahmed, A ;

Thompson, J ;

Emiliusen, L ;

Murphy, S ;

Beauchamp, RD ;

Suzuki, K ;

Alemany, R ;

Harrington, K ;

Vile, RG .

NATURE BIOTECHNOLOGY, 2003, 21 (07) :771-777

[3]

Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185

[4] Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice [J].

Bequet-Romero M. ;

Ayala M. ;

Acevedo B.E. ;

Rodríguez E.G. ;

López Ocejo O. ;

Torrens I. ;

Gavilondo J.V. .

Angiogenesis, 2007, 10 (1) :23-34

[5] Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center [J].

Bergman, PJ ;

Camps-Palau, MA ;

McKnight, JA ;

Leibman, NF ;

Craft, DM ;

Leung, C ;

Liao, J ;

Riviere, I ;

Sadelain, M ;

Hohenhaus, AE ;

Gregor, P ;

Houghton, AN ;

Perales, MA ;

Wolchok, JD .

VACCINE, 2006, 24 (21) :4582-4585

[6]

Bergman PJ, 2003, CLIN CANCER RES, V9, P1284

[7]

Bertin S, 2008, INT J MOL MED, V21, P309

[8] Immunoregulatory T Cells: Role and Potential as a Target in Malignancy [J].

Beyer, Marc ;

Schultze, Joachim L. .

CURRENT ONCOLOGY REPORTS, 2008, 10 (02) :130-136

[9] Double-blinded, placebo-controlled plasmid GHRH trial for cancer-associated anemia in dogs [J].

Bodles-Brakhop, Angela M. ;

Brown, Patricia A. ;

Pope, Melissa A. ;

Draghia-Akli, Ruxandra .

MOLECULAR THERAPY, 2008, 16 (05) :862-870

[10] Characterization of antigen-specific immune responses induced by Canarypox virus Vaccines [J].

Bos, Rinke ;

Van Duikeren, Suzanne ;

Van Hall, Thorbald ;

Lauwen, Marjolein M. ;

Parrington, Mark ;

Berinstein, Neil L. ;

McNeil, Bryan ;

Melief, Cornelis J. M. ;

Verbeek, J. Sjef ;

Van der Burg, Sjoerd H. ;

Offringa, Rienk .

JOURNAL OF IMMUNOLOGY, 2007, 179 (09) :6115-6122

← 1 2 3 4 5 6 7 8 9 10 →